AstraZeneca (AZN) Price & Analysis

Compare

7,174 Followers

AZN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$61.24 - $87.68

Previous CloseN/A

Volume1.80M

Average Volume (3M)4.03M

Market Cap

$217.69B

Enterprise Value$244.54B

Total Cash (Recent Filing)$5.39B

Total Debt (Recent Filing)$31.29B

Price to Earnings (P/E)28.4

Beta0.33

Next Earnings

Jul 29, 2025

EPS Estimate

1.09

Last Dividend Ex-Date

Feb 21, 2025

Dividend Yield2.95%

Share Statistics

EPS (TTM)1.25

Shares Outstanding3,101,341,300

10 Day Avg. Volume3,984,045

30 Day Avg. Volume4,027,288

Financial Highlights & Ratios

PEG Ratio2.71

Price to Book (P/B)5.31

Price to Sales (P/S)0.00

P/FCF Ratio22.51

Enterprise Value/Market Cap1.12

Enterprise Value/Revenue1.17

Enterprise Value/Gross Profit5.46

Enterprise Value/Ebitda3.82

Forecast

1Y Price Target

$91.00

Price Target Upside26.85% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

AstraZeneca News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical TrialsDESTINY-Breast09 demonstrated a highly statistically significant and clinically meaningful improvement in PFS for Enhertu + pertuzumab vs the control arm standard of care in patients with 1L HER2+ metastatic breast cancer.

Market ExpansionAZN will obtain full rights to roxadustat in China, a HIF inhibitor approved for the treatment of anemia in chronic kidney disease.

New Product PotentialMore recently launched products including Ultomiris, Enhertu, Saphnelo, Tezspire, and Beyfortus collectively have $15B+ in sales potential to AZN in 2030.

Bears Say

Clinical Trial DiscontinuationThe discontinuation of the CAPItello-280 Ph 3 trial evaluating Truqap in patients with metastatic castration-resistant prostate cancer was announced.

Product RevenueThe company reported product revenues of $12,875bn, below consensus estimates of $13,145bn by approximately 2%.

Regulatory RisksCurrent investor concerns mainly revolve around risks to the China business due to alleged improper practices by former employees.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

―

Insiders

5.71% Mutual Funds

0.24% Other Institutional Investors

93.11% Public Companies and Individual Investors

Detailed Ownership Overview >

AZN FAQ

What was AstraZeneca’s price range in the past 12 months?

AstraZeneca lowest stock price was $61.24 and its highest was $87.67 in the past 12 months.

What is AstraZeneca’s market cap?

AstraZeneca’s market cap is $217.69B.

When is AstraZeneca’s upcoming earnings report date?

AstraZeneca’s upcoming earnings report date is Jul 29, 2025 which is in 13 days.

How were AstraZeneca’s earnings last quarter?

AstraZeneca released its earnings results on Apr 29, 2025. The company reported $1.245 earnings per share for the quarter, beating the consensus estimate of $1.116 by $0.129.

Is AstraZeneca overvalued?

According to Wall Street analysts AstraZeneca’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does AstraZeneca pay dividends?

AstraZeneca pays a Semiannually dividend of $1.519 which represents an annual dividend yield of 2.95%. See more information on AstraZeneca dividends here

What is AstraZeneca’s EPS estimate?

AstraZeneca’s EPS estimate is 1.09.

How many shares outstanding does AstraZeneca have?

AstraZeneca has 3,101,341,300 shares outstanding.

What happened to AstraZeneca’s price movement after its last earnings report?

AstraZeneca reported an EPS of $1.245 in its last earnings report, beating expectations of $1.116. Following the earnings report the stock price went up 2.545%.

Which hedge fund is a major shareholder of AstraZeneca?

Currently, no hedge funds are holding shares in AZN

AstraZeneca Stock Smart Score

Outperform

Fundamentals

Return on Equity

19.81%

Trailing 12-Months

Asset Growth

3.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

AstraZeneca

AstraZeneca (AZN) is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company primarily focuses on the discovery, development, and commercialization of prescription medicines in three main therapy areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

AZN Company Deck

AZN Earnings Call

Q1 2025

0:00 / 0:00

AZN Stock 12 Month Forecast

Average Price Target

$91.00

▲(26.85%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"63":"$63","98":"$98","71.75":"$71.8","80.5":"$80.5","89.25":"$89.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":97,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$97.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":91,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$91.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$79.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[63,71.75,80.5,89.25,98],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.46,73.42461538461538,75.38923076923076,77.35384615384615,79.31846153846153,81.28307692307692,83.2476923076923,85.21230769230769,87.17692307692307,89.14153846153846,91.10615384615384,93.07076923076923,95.03538461538461,{"y":97,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.46,72.96307692307691,74.46615384615384,75.96923076923076,77.4723076923077,78.97538461538461,80.47846153846153,81.98153846153846,83.48461538461538,84.9876923076923,86.49076923076923,87.99384615384615,89.49692307692308,{"y":91,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,71.46,72.03999999999999,72.61999999999999,73.19999999999999,73.78,74.36,74.94,75.52,76.1,76.67999999999999,77.26,77.84,78.42,{"y":79,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":76.4,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.6,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.41,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.58,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.43,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.11,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.78,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.21,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.51,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.46,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >